Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: COPAXONE

« Back to Dashboard

Copaxone is a drug marketed by Teva Pharms Usa and is included in one NDA. It is available from one supplier. There are ten patents protecting this drug and two Paragraph IV challenges.

The generic ingredient in COPAXONE is glatiramer acetate. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the glatiramer acetate profile page.

Summary for Tradename: COPAXONE

Patents:10
Applicants:1
NDAs:1
Suppliers: see list1
2013 Sales:$3,697,182,000

Clinical Trials for: COPAXONE

A Study to Evaluate the Safety and Effectiveness of Novantrone Therapy Followed by Copaxone for Multiple Sclerosis.
Status: Completed Condition: Relapsing Remitting Multiple Sclerosis

Safety and Efficacy Study of Copaxone Administered in Combination With Minocycline
Status: Completed Condition: Relapse Remitting Multiple Sclerosis

Phase IV Study, Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRI
Status: Active, not recruiting Condition: Multiple Sclerosis

A Study to Evaluate the Impact on Skin (Injection Site) Reactions of Taking an Antihistamine (Zyrtec®) or Placebo Prior to Daily Injections of Copaxone®.
Status: Completed Condition: Multiple Sclerosis

Evaluation of Two Glatiramer Acetate (GA) Formulations in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients
Status: Completed Condition: Multiple Sclerosis

Evaluate Early Glatiramer Acetate Treatment in Delaying Conversion to Clinically Definite Multiple Sclerosis of Subjects Presenting With Clinically Isolated Syndrome
Status: Completed Condition: Multiple Sclerosis

Assessment Study of Steroid Effect in Relapsing Multiple Sclerosis Subjects Treated With Glatiramer Acetate
Status: Terminated Condition: Relapsing Remitting Multiple Sclerosis

Efficacy and Safety of GTR in Comparison to Copaxone®
Status: Active, not recruiting Condition: Multiple Sclerosis

Anti-Inflammatory Type II Monocyte Induction by Glatiramer Acetate (Copaxone) Treatment of Multiple Sclerosis
Status: Completed Condition: Multiple Sclerosis

Treatment of Multiple Sclerosis With Copaxone and Albuterol
Status: Completed Condition: Autoimmune Diseases; Multiple Sclerosis

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva Pharms Usa
COPAXONE
glatiramer acetate
INJECTABLE;SUBCUTANEOUS020622Feb 12, 2002RXYes8,367,605<disabled>Y<disabled>
Teva Pharms Usa
COPAXONE
glatiramer acetate
INJECTABLE;SUBCUTANEOUS020622Jan 28, 2014RXYes8,232,250<disabled><disabled>
Teva Pharms Usa
COPAXONE
glatiramer acetate
INJECTABLE;SUBCUTANEOUS020622Jan 28, 2014RXYes8,367,605<disabled>Y<disabled>
Teva Pharms Usa
COPAXONE
glatiramer acetate
INJECTABLE;SUBCUTANEOUS020622Feb 12, 2002RXYes6,054,430<disabled><disabled>
Teva Pharms Usa
COPAXONE
glatiramer acetate
FOR SOLUTION;SUBCUTANEOUS020622Dec 20, 1996DISCNNo6,054,430<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: COPAXONE

Drugname Dosage Strength RLD Submissiondate
glatiramer acetateInjection40 mg/mL, 1 mL pre-filled syringeCopaxone2/26/2014
glatiramer acetateInjection40 mg/mL, 1 mL pre-filled syringeCopaxone1/29/2014
« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology

`abc